Adamas Presents Final Results from the Two-Year, Phase 3 Open-Label Study of GOCOVRI™ in Parkinson’s Disease Patients with Dyskinesia GOCOVRI was generally well tolerated and the safety profile was consistent with previously reported data for up to two yearsResults show a comparable 35% reduction from baseline in dyskinesia and OFF...

Adamas Reports Second Quarter 2018 Financial Results - GOCOVRI™ (amantadine) extended release capsules product sales reached $7.6 million for the second quarter - EMERYVILLE, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc....